HONG KONG – Osaka, Japan-based Ono Pharmaceutical Co. Ltd. entered a license agreement with Bristol-Myers Squibb Co. for the development and commercialization of its compound, ONO-4578, a selective antagonist of EP4, a prostaglandin E2 (PGE2) receptor.